Mealey's (May 23, 2022, 1:15 PM EDT) -- PASADENA, Calif. — A Ninth Circuit U.S. Court of Appeals panel on May 19 affirmed a federal district court’s dismissal of shareholder claims against a drug maker and certain of its senior executives over alleged misstatements the defendants made regarding Phase 1 clinical trial results for the company’s cancer treatment drug candidate, ruling that the pension funds failed to sufficiently plead falsity or loss causation for their federal securities law claims....